18 results about "Octadecadienoic Acid" patented technology

The invention relates to a plasma metabolite composition for auxiliary diagnosis of sub-clinical mastitis of dairy cows and application of the plasma metabolite composition. The plasma metabolite combination is a first combination and / or a second combination, and the first combination is composed of glyceryl monolinoleate, 2-methylthiophene, L-cystine, (S)-(+)-citramalic acid, 9-hydroxy-10, 12-octadecadienoic acid, 16-hydroxyhexadecanoic acid, tyrosine hydroxyproline, stearoyl serotonin and histamine; the first composition is composed of 4, 5-dimethyl-2, 4, 5-trimethyloxazole, 12, 13-epoxy octadecadienoic acid, 2-cyclotetradecene-1-ketone, 4 [alpha]-carboxyl-5 [alpha]-cholest-8-ene-3 [beta]-alcohol, N-arachidonyl dopamine d8, 9 (Z) and 11 (E)-conjugated linoleic acid, and the second composition is composed of 2, 5-dihydro-2, 4, 5-trimethyloxazole, 12, 13-epoxy octadecadienoic acid, 2-cyclotetradecene-1-ketone, 4 [alpha]-carboxyl-5 [alpha]-cholest-8-ene-3 [beta]-alcohol, N-arachidonyl dopamine A product prepared based on the plasma metabolite composition and used for auxiliary diagnosis of cow subclinical mastitis is simple in use method and high in accuracy, can be used for assisting a milk somatic cell number method to diagnose cow subclinical mastitis, and reduces the probability of false negative and false positive.

To provide lipid nanoparticle-based compositions and methods useful for delivery of CRISPR / Cas gene editing components.SOLUTION: A lipid nanoparticle (LNP) composition comprises: mRNA encoding a Cas nuclease; guide RNA nucleic acid; and a plurality of component lipids comprising the following: 35 mol% to 55 mol% of lipid A, which is (9Z,12Z)-3-((4,4-bis(octyloxy)butanoyl)oxy)-2-((((3-(diethylamino)propoxy)carbonyl)oxy)methyl)propyl octadeca-9,12-dienoate; 35 mol% to 55 mol% of a helper lipid; 5 mol% to 15 mol% of a neutral lipid; and 1 mol% to 5 mol% of a stealth lipid.SELECTED DRAWING: None

The objective is to provide a plant activator for soybeans that can increase soybean yield. [Solution] A plant activator for soybeans comprising at least one compound selected from ketooctadecadienoic acid or its derivatives, structural isomers, or salts thereof.

The invention provides an application of 10E, 12Z-octadecadienoic acid in inhibition of inflammatory reactions, and the inflammatory reactions comprise macrophage inflammatory reactions induced by lipopolysaccharide. According to the invention, a mouse mononuclear macrophage RAW264.7 cell inflammatory response model is constructed. The method comprises the following steps: firstly, measuring CC50 of 10E, 12Z-octadecadienoic acid by a CCK-8 method; 10E, 12Z-octadecadienoic acid is used for pretreating macrophages for 24 hours before lipopolysaccharide stimulation at the final concentration of 25 mu mol / L to 100 mu mol / L, qPCR (quantitative polymerase chain reaction) and ELISA (enzyme-linked immuno sorbent assay) experiments prove that the 10E, 12Z-octadecadienoic acid plays an anti-inflammatory role by inhibiting mRNA (messenger ribonucleic acid) expression and protein secretion of IL-6, IL-1beta and / or TNF-alpha, and the anti-inflammatory effect is optimal at the final concentration of 100 mu mol / L. The 10E, 12Z-octadecadienoic acid is a single unmodified fatty acid isomer, is clear in structure, good in anti-inflammatory effect repeatability and good in biocompatibility, and can reduce adverse reactions compared with traditional anti-inflammatory drugs; compared with existing fatty acid anti-inflammatory components, the composition is clear in component and simple and convenient to prepare. The application scenarios of the invention cover the development of anti-inflammatory drugs, functional foods and biological agents.

The invention belongs to the technical field of pharmaceutical chemistry and natural product separation, and provides a phellinus igniarius extract with anti-influenza virus activity. The extract is 9-oxo-10E, 12E-octadecadienoic acid, or osmundone, and the extract is a compound shown in the description. The phellinus igniarius is a sporocarp or a mycelium of inonotus hispidus, and the phellinus igniarius is a sporocarp or a mycelium of inonotus hispidus. The monomeric compound obtained by separating the phellinus igniarius extract contains an inhibitory component with relatively high H1N1 influenza virus resisting activity, the H1N1 influenza virus inhibition rate of the monomeric compound shows an S-shaped curve, and the inhibition effect is remarkable along with the increase of the concentration. The invention provides two potential antiviral active compounds which have the potential of further development.

The present invention discloses an application and a kit for differential histoproteins and / or metabolites of pigmented villonodular synovitis; the differential histoproteins include at least one of the following proteins: TNFSF11, cathepsin K, and adhesion G protein-coupled receptor E5; the differential metabolites include at least one of the following products: 13-hydroxyperoxylinoleic acid and octadecadienoic acid; the present invention provides a new screening marker for pigmented villonodular synovitis (PVNS) through proteomics and metabolomics, which can achieve effective screening for pigmented villonodular synovitis; the obtained screening marker is used in a screening kit, which only needs synovial fluid as a test sample, can quickly perform screening and detection, and has the advantages of high efficiency and simple detection.

The invention relates to the technical field of biologic detection of metabolomics, in particular to an OSAHS metabolism marker, a diagnosis model and application of the OSAHS metabolism marker and the diagnosis model. The metabolic marker comprises a red blood cell metabolite and / or a plasma metabolite; erythrocyte metabolites comprise L-aspartic acid, D-ribose-5-diphosphoric acid, cadaverine, 12, 13-epoxy octadecenoic acid, L-arginine, N-acetylmethionine, 5-hydroxyeicosatetraenoic acid, 13-oxo-9Z, 9, 10-tetrahydroxy-9Z, 9, 10-tetrahydroxy-9Z, 9, 10-tetrahydroxy-9Z, 9, 10-tetrahydroxy-9Z, 9, 10-tetrahydroxy-9Z, 10-tetrahydroxy-9Z, the component A is one or more of 11E-octadecadienoic acid, inosine monophosphate, nicotinamide, alpha-lactose, sphingosine, hydroxy octadecadienoyl or glyceraldehyde-3-phosphoric acid; the plasma metabolite is prepared from one or more of fumaric acid, cadaverine, L-aspartic acid, malic acid, sphingosine-1-phosphoric acid, L-arginine, cysteine-S-sulfate, thiosulfate, gamma-glutamyl alanine, galacturonic acid or vitamin B2.

The invention discloses a high-calcium, low-cholesterol and long-shelf-life functional egg and a production method thereof, and relates to the technical field of functional eggs and production methods thereof. The method specifically comprises the step of feeding laying hens in an egg producing period with daily ration rich in polyunsaturated fatty acid deposition calcium such as cis-octadecadienoic acid, alpha cis-octadecadienoic acid and gamma cis-octadecatrienoic acid and rich in various oligosaccharides, autotrophic compound beneficial bacterium preparations and the like to obtain the functional eggs. The composition is rich in polyunsaturated fatty acids such as cis-octadecadienoic acid, alpha cis-octadecadienoic acid, gamma cis-octadecatrienoic acid and the like. The functional egg disclosed by the invention has the advantages of low cholesterol content, high calcium content and no yellow scattering phenomenon after being stored for 30 days at the temperature of 37 DEG C during the shelf life.

The present invention provides a method for determining whether a subject is suffering from post-traumatic stress disorder (PTSD) or acute stress disorder (ASD), the method comprising measuring, in a sample derived from the subject, the amount of at least one selected from the group consisting of 12-hydroxy-5,8,10,14-eicosatetraenoic acid (12-HETE), 15-hydroxy-5,8,11,13-eicosatetraenoic acid (15-HETE), and 13-hydroxy-9(Z),11(E)-octadecadienoic acid (13-(Z,E)-HODE).

The invention belongs to the technical field of biomedicine, and particularly relates to a diagnosis model and application thereof in diagnosis of aortic aneurysm. The diagnostic model comprises a metabolic marker in a detection sample, the metabolic marker comprises gamma-L-glutamyl-L-alanine and / or (2-hydroxy-2-{9-hydroxy-7-oxo-2H, 3H, 7H-furo [3, 2-g] chroman-2-yl} propoxy) sulfonic acid, preferably, the metabolic marker further comprises hypoxanthine and / or 13-hydroperoxide octadecadienoic acid (1-), and the metabolic marker comprises gamma-L-glutamyl-L-alanine and / or (2-hydroxy-2-{9-hydroxy-7-oxo-2H, 3H, 7H-furo [3, 2-g] chroman-2-yl} propoxy) sulfonic acid. The AUC value of the metabolic marker for diagnosing the aortic aneurysm is higher than 0.8 when the metabolic marker is independently used or jointly used, and the AUC value of the metabolic marker and the AUC value of the metabolic marker and the AUC value of the metabolic marker have high specificity and sensitivity.

A method to synthesize a silver nanohybrid material. The method includes mixing a nitrate solution with a citrate solution to form silver nanoparticles (AgNPs). The method further includes esterifying a first mixture including octadecanoic acid, octadec-9-enoic acid, and octadeca-9,12-dienoic acid with caffeic acid in the presence of an acid catalyst and a solvent to form an unsaturated carboxylic acid mixture including first, second, and third acrylic acid derivatives. The method includes reacting the unsaturated carboxylic acid mixture with ethylene glycol to form a second mixture including first, second, and third ester derivatives. The method further includes mixing the AgNPs with the second mixture to form a third mixture. The method includes evaporating water from the third mixture to form the silver nanohybrid material. The silver nanohybrid material includes a AgNP core covered with the first, second, and third ester derivatives bonded to the AgNP core.

The invention discloses an application of 9 (Z), 11 (E)-octadecadienoic acid in treating and / or improving alcoholic liver injury. The traditional Chinese medicine composition is good in druggability, clear in structure and easy in quality control and standardized production; the compound is relatively good in stability, has targeting optimization potential and good bioavailability, and has dual value potential of preventing and treating ALD (Atomic Lymphosis Disease).

To provide: a method for increasing the accumulation of 9,10-ketol-octadecadienoic acid (KODA) in plant individuals, tissues, or cells; a KODA production system; and a method for producing plants with increased stress resistance.SOLUTION: The present invention provides a method for increasing accumulation of KODA that includes a step of maintaining plant individuals, tissues, or cells in a medium under a phosphorus-deficient condition. The present invention also provides a system for producing KODA that includes plant individuals, tissues, or cells, including the 9-LOX gene and / or AOS gene, maintained in a medium with a dissolved phosphorus level of less than 1 mM. The present invention also provides a method for producing a plant with increased stress resistance that includes the steps of: introducing the 9-LOX gene and / or AOS gene to the plant and cultivating the plant in a medium under the phosphorus-deficient condition.SELECTED DRAWING: Figure 1

A method to synthesize a silver nanohybrid material. The method includes mixing a nitrate solution with a citrate solution to form silver nanoparticles (AgNPs). The method further includes esterifying a first mixture including octadecanoic acid, octadec-9-enoic acid, and octadeca-9,12-dienoic acid with caffeic acid in the presence of an acid catalyst and a solvent to form an unsaturated carboxylic acid mixture including first, second, and third acrylic acid derivatives. The method includes reacting the unsaturated carboxylic acid mixture with ethylene glycol to form a second mixture including first, second, and third ester derivatives. The method further includes mixing the AgNPs with the second mixture to form a third mixture. The method includes evaporating water from the third mixture to form the silver nanohybrid material. The silver nanohybrid material includes a AgNP core covered with the first, second, and third ester derivatives bonded to the AgNP core.

The application discloses a wheat Tilletia indica-specific biomarker combination, a screening method and application thereof, and the biomarker combination comprises 20-hydroxyarachidonic acid, 1-octadecyl lysophosphatidic acid, linolenic acid, 13-hydroxydocosahexaenoic acid, 4-methoxy estrone, hypoxanthine, 3-hydroxymyristic acid, beta-ecdysterone, 17-phenyltrinorprostaglandin F2 alpha cyclopropylmethylamide, 11,12-dihydroxyeicosatrienoic acid and oxidized octadecadienoic acid. When the biomarker combination is used for identifying Tilletia indica, the time-consuming long and the accuracy easily interfered by the spore development stage limitations of traditional morphological identification are overcome; in view of the molecular level identification difficulty caused by the high genome homology of Tilletia indica and Tilletia controversa, the application digs the feature difference at the level of metabolomics, and constructs a specific chemical fingerprint, so that the technical bottleneck that the close relatives are difficult to accurately distinguish is effectively solved.

The present invention belongs to the field of medicinal chemistry and natural product separation technology, and provides a phellinus linteus extract with anti-influenza virus activity. The extract is 9-oxo-10E, 12E-octadecadienoic acid, or porphyrone. The phellinus linteus is a fungus of the species Porites crassifolia ( Unfinished hairy ) fruiting bodies or mycelia. The monomeric compounds isolated from the extract of Phellinus igniarius contain components with high inhibitory activity against the H1N1 influenza virus. Their inhibition rate against the H1N1 influenza virus exhibits an S-shaped curve, with significant inhibition increasing with increasing concentration. The present invention provides two potential antiviral compounds with potential for further development.

The invention relates to an excrement metabolite composition for auxiliary diagnosis of sub-clinical mastitis of dairy cows and application of the excrement metabolite composition. The excrement metabolite combination is a first combination and / or a second combination, and the first combination is composed of 9 (S)-hydroxyl peroxide octadecadienoic acid, 25-hydroxyl cholesterol, dodecanedioic acid, deoxycytidine and cis-1, 2-dihydronaphthalene-1, 2-diol; and the second composition is composed of glycyl leucine, 3-methyl-L-tyrosine, L-3-cyano alanine, 2-(methyl amino) benzoic acid, N6-methyl lysine, 5, 6-dihydroepoxy eicosatrienoic acid, phenylethylamine, and 12, 13-dihydroxy octadecadienoic acid. The product prepared on the basis of the excrement metabolite composition and used for auxiliary diagnosis of cow subclinical mastitis is simple in use method and high in accuracy, and can be used for assisting a milk somatic cell number method to diagnose cow subclinical mastitis, the probability of false negative and false positive occurrence is reduced, and the accuracy of a subclinical mastitis diagnosis result is improved.

To provide ketooctadecadienoic acid production methods that synthesizes ketooctadecadienoic acid safely, stably, and efficiently.SOLUTION: Provided is a ketooctadecadienoic acid production method comprising (A) allowing an enzyme material containing lipoxygenase to act on a raw material containing fatty acids, and (b) stopping the enzymatic reaction of the lipoxygenase contained in the reaction mixture obtained in the step (a).SELECTED DRAWING: None